Patients With mCRPC Need Effective and Tolerable Treatments Earlier
What Is the Unmet Need in Treating mCRPC?
Not an actual patient.
- A majority of patients die within 2 years of an mCRPC diagnosis1
- More than half of patients with mCRPC will receive only one life-prolonging therapy2
- mCRPC is associated with fast progression, which can disrupt patients’ lives2,3
Watch Dr Vaishampayan, Dr Reichard, and Dr Franklin speak about the importance of early treatment for patients with mCRPC below.
ARPI, androgen receptor pathway inhibitor; mCRPC, metastatic castration-resistant prostate cancer.
Importance of Early Action in Care for Patients With mCRPC
PLUVICTO Benefits
PLUVICTO: The first and only PSMA-targeted RLT FDA approved after only 1 ARPI4
PLUVICTO targets PSMA, a biomarker overexpressed in more than 80% of men with prostate cancer4-6
In the PSMAfore trial after only 1 ARPI,
PLUVICTO more than doubled median rPFS vs a change in ARPI7
Updated exploratory analysis: Median rPFS was 11.6 months with PLUVICTO vs 5.6 months with a change in ARPI (HR=0.49 [95% CI, 0.39-0.61])7,*
PLUVICTO has a favorable safety profile and proven tolerability7
Grade ≥3 AE rates were lower in the PLUVICTO group with a longer median duration of exposure7
6% permanent discontinuation rate due to an AE; 4% had a dose modification due to an AE; 12% had a dose interruption due to an AE4,7
Most common ARs (≥20%) in PSMA+ mCRPC after 1 ARPI: dry mouth, fatigue, nausea, constipation, decreased appetite, and arthralgia4
PLUVICTO can be delivered within 5 days of order placement,† so your patients can begin treatment as soon as possible8
Choose PLUVICTO: Proven in 2 large phase 3 trials and ~25K patients treated from launch to date4,7,9,10,‡
AE, adverse event; AR, adverse reaction; HR, hazard ratio; PET, positron emission tomography; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive; RLT, radioligand therapy; rPFS, radiographic progression-free survival.
*Exploratory rPFS analysis was performed with a median follow-up period of 24 months vs the primary analysis at 7 months. This analysis was not controlled for Type-I error.7
†Exceptions may apply for syringe form and select geographic locations.8
‡Based on data from October 2025.10